SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for Clinical Trial NCT02824952

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC - a Phase 2 Open-label Study

Patients will receive AZD9291 at a dose of 80 mg once daily. Systemic evaluation will be done by PET-CT scan after 6 weeks. In responding patients AZD9291 will be given orally 80 mg daily for 12 weeks. Non-responding patients will receive AZD9291 for the period of 6 or 12 weeks (according to the results of response assessment at each time-point).

NCT02824952 Lung Cancer

1 Interventions

Name: Tagrisso

Description: taking orally everyday for 6 or 12 weeks.
Type: Drug
Group Labels: 1

Tagrisso 80 mg

Primary Outcomes

Description: assessed by PET-CT

Measure: Overall Response Rate as defined by RECIST 1.1

Time: 12 weeks

Secondary Outcomes

Measure: mPFS measured by Kaplan-Meier method.

Time: 2 years

Measure: Comparing GTV (Gross tumor volume) before and after the neoadjuvant therapy

Time: 2 years

Purpose: Treatment

Allocation: N/A

Single Group Assignment

There is one SNP


1 T790M

3. Treatment-naïve stage IIIA/B NSCLC with an activating sensitizing EGFR mutation/T790M • Uncommon sensitizing EGFR mutations are allowed. --- T790M ---

Exclusion Criteria: 1. EGFR TKI - resistant EGFR mutations (e.g., insertion in exon 20) • T790M is allowed. --- T790M ---

HPO Nodes